ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 185 filers reported holding ASCENDIS PHARMA A/S in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,809,593 | +30.5% | 19,325 | +49.5% | 0.01% | +66.7% |
| Q1 2023 | $1,386,247 | -90.3% | 12,929 | -89.0% | 0.00% | -90.6% |
| Q4 2022 | $14,328,658 | +825.0% | 117,323 | +682.2% | 0.03% | +700.0% |
| Q3 2022 | $1,549,000 | +30.4% | 15,000 | +17.3% | 0.00% | +33.3% |
| Q2 2022 | $1,188,000 | -26.1% | 12,785 | -6.7% | 0.00% | 0.0% |
| Q1 2022 | $1,608,000 | -47.8% | 13,705 | -40.1% | 0.00% | -57.1% |
| Q4 2021 | $3,080,000 | -10.1% | 22,895 | +6.6% | 0.01% | -12.5% |
| Q3 2021 | $3,425,000 | +50.8% | 21,487 | +24.4% | 0.01% | +33.3% |
| Q2 2021 | $2,271,000 | +143.1% | 17,267 | +138.2% | 0.01% | +100.0% |
| Q1 2021 | $934,000 | -92.8% | 7,250 | -90.7% | 0.00% | -92.9% |
| Q4 2020 | $12,973,000 | +65.7% | 77,788 | +53.3% | 0.04% | +35.5% |
| Q3 2020 | $7,829,000 | +1075.5% | 50,731 | +1026.9% | 0.03% | +933.3% |
| Q2 2020 | $666,000 | – | 4,502 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
| RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
| Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
| BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
| Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
| Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
| Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
| Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
| Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
| Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |